Your browser is no longer supported. Please, upgrade your browser.
Settings
JNJ Johnson & Johnson daily Stock Chart
JNJ [NYSE]
Johnson & Johnson
IndexDJIA S&P500 P/E26.00 EPS (ttm)5.40 Insider Own0.07% Shs Outstand2.67B Perf Week-0.87%
Market Cap374.55B Forward P/E15.35 EPS next Y9.15 Insider Trans0.17% Shs Float2.65B Perf Month1.47%
Income14.68B PEG4.01 EPS next Q2.42 Inst Own69.50% Short Float0.50% Perf Quarter2.30%
Sales81.59B P/S4.59 EPS this Y7.60% Inst Trans-0.22% Short Ratio2.03 Perf Half Y8.76%
Book/sh22.16 P/B6.34 EPS next Y6.35% ROA9.60% Target Price149.17 Perf Year15.77%
Cash/sh5.75 P/C24.42 EPS next 5Y6.48% ROE23.80% 52W Range120.11 - 148.99 Perf YTD8.83%
Dividend3.80 P/FCF42.40 EPS past 5Y3.10% ROI17.00% 52W High-4.98% Beta0.71
Dividend %2.71% Quick Ratio1.10 Sales past 5Y2.70% Gross Margin66.90% 52W Low17.87% ATR2.06
Employees135100 Current Ratio1.40 Sales Q/Q0.10% Oper. Margin20.80% RSI (14)61.28 Volatility0.92% 1.50%
OptionableYes Debt/Eq0.50 EPS Q/Q-13.00% Profit Margin18.00% Rel Volume0.94 Prev Close140.45
ShortableYes LT Debt/Eq0.47 EarningsJul 16 BMO Payout65.60% Avg Volume6.60M Price141.57
Recom2.30 SMA203.14% SMA502.51% SMA2003.12% Volume1,581,154 Change0.80%
May-28-19Initiated Goldman Buy
Jan-23-19Reiterated Barclays Equal Weight $137 → $135
Jul-12-18Upgrade Goldman Sell → Neutral
Jun-27-18Initiated Bernstein Mkt Perform $129
Apr-23-18Reiterated Citigroup Neutral $146 → $134
Apr-18-18Reiterated Stifel Hold $145 → $135
Jan-24-18Reiterated Stifel Hold $142 → $145
Jan-12-18Reiterated Wells Fargo Outperform $155 → $160
Jan-02-18Downgrade JP Morgan Overweight → Neutral
Oct-18-17Reiterated Stifel Hold $140 → $142
Oct-18-17Reiterated RBC Capital Mkts Outperform $144 → $147
Oct-18-17Reiterated Leerink Partners Outperform $150 → $165
Oct-16-17Reiterated Jefferies Buy $157 → $160
Oct-11-17Upgrade Jefferies Hold → Buy
Oct-09-17Upgrade Wells Fargo Market Perform → Outperform
Sep-25-17Initiated Citigroup Neutral $140
Sep-20-17Downgrade Goldman Neutral → Sell $125 → $130
Jul-21-17Downgrade BTIG Research Neutral → Sell $110
Jul-21-17Downgrade Alembic Global Advisors Neutral → Underweight
Jul-20-17Resumed Credit Suisse Outperform $148
Jun-19-19 01:30PM  Billions at Stake in Opioid Suits, But It's No Tobacco Windfall Bloomberg
09:06AM  Big Drugmakers That May Tread the M&A Path After Pfizer Zacks
Jun-18-19 04:53PM  5 Large-Cap Stocks With Low Price-Sales Ratios GuruFocus.com
03:57PM  Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results PR Newswire
Jun-17-19 05:45PM  Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know Zacks
05:26PM  J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study Zacks
Jun-16-19 06:17AM  5 Top Stocks to Protect Your Portfolio TipRanks
Jun-14-19 09:23AM  Medidata (MDSO) to be Acquired by Dassault for $5.8 Billion Zacks
08:42AM  Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod Zacks
Jun-13-19 04:12PM  The Opioid Epidemic Will Be A Yearslong Overhang For These Pharma Stocks Investor's Business Daily
11:59AM  The Opioid Epidemic Will Be A Yearslong Overhang For These Pharma Stocks Investor's Business Daily
10:56AM  Johnson & Johnson Made the Right Call in Fighting Oklahoma Over Opioids, Analyst Says Barrons.com
07:00AM  Market Morning: Huawei Strikes Back, No on No No Deal, Ancient Chinese Stoners, Crowded CrowdStrike Market Exclusive
07:00AM  Johnson & Johnson and Cisco Directors Are Buying Up Stock Barrons.com
Jun-12-19 07:01PM  Jim Cramer: A Tale of Two Stocks TheStreet.com
04:17PM  Pharma Giant Nears Two-Decade Low As Opioid Settlement Remains In Limbo Investor's Business Daily
12:11PM  Why This Dow Jones Pharmaceutical Giant Is Trying To Break Out Investor's Business Daily
11:10AM  Teva Retests Lows After Judge Declines Settlement Offer Investopedia
08:28AM  Traders Look to Buy Global Health Care Stocks Investopedia
Jun-11-19 05:45PM  Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know Zacks
04:06PM  13 Blue-Chip Stocks With Risks You Need to Watch Kiplinger
10:40AM  Johnson & Johnson Is A Massive Pharma Stock But Should You Buy It? Investor's Business Daily
07:34AM  The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering Benzinga
Jun-10-19 06:30AM  Here's Why Arrowhead Pharmaceuticals Surged 31.9% in May Motley Fool
Jun-07-19 07:48PM  Why Investors Should Keep an Eye on the Oklahoma Opioid Trial Against Johnson & Johnson Motley Fool
10:31AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, Chevron, Adobe, Las Vegas Sands and Southern Copper Zacks
10:21AM  Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache Zacks
09:36AM  Teva and J&J Stocks Were Hit by Opioid Worries. What Could Come Next. Barrons.com
08:00AM  Should You Be Holding Johnson & Johnson (NYSE:JNJ)? Simply Wall St.
07:00AM  How Funds That Chase the Hottest Stocks Can Still Lag Behind Barrons.com
06:58AM  UPDATE 3-Drugmaker Sanofi hires Hudson from Novartis as CEO Reuters
02:16AM  CORRECTED-UPDATE 2-Drugmaker Sanofi appoints Novartis' Hudson as CEO Reuters
Jun-06-19 06:03PM  Are Hedge Funds Going To Get Burned By Johnson & Johnson (JNJ) ? Insider Monkey
04:56PM  Celgene & Acceleron's BLA for Luspatercept Accepted by FDA Zacks
02:19PM  Top Stock Reports for Johnson & Johnson, Chevron & Adobe Zacks
Jun-05-19 09:17PM  Opioid maker Insys agrees to pay $225m to settle US criminal cases Financial Times
05:45PM  Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know Zacks
03:53PM  Christopher Browne: Finding the Silver Lining When Markets Dip GuruFocus.com
09:44AM  Behind (and above) the scenes at BIO 2019 exhibit hall (Photos) American City Business Journals
09:39AM  Johnson & Johnson Releases 2018 Health for Humanity Report PR Newswire
09:15AM  Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy? Zacks
Jun-04-19 03:49PM  St. Louis-based firm wins $325M in Johnson & Johnson talc trial American City Business Journals
11:42AM  Obalon Clinches First US Patent For Obesity Treatment Placement System Benzinga
05:00AM  Mini-tender spree of lowball stock offers lands on Lockheed American City Business Journals
01:39AM  Pharma groups combine to promote drug discovery with AI Financial Times
Jun-03-19 04:51PM  Is Johnson & Johnson a Buy? GuruFocus.com
04:25PM  Dow Jones Today: 4 Big Stocks That Could Be in Big Trouble InvestorPlace
04:21PM  6 Large-Cap Stocks Beating the Market GuruFocus.com
09:30AM  MyPhillyLawyer Helps Secure $80 Million Victory for Transvaginal Mesh Patient PR Newswire
Jun-02-19 11:40AM  Johnson & Johnson: Follow Warren Buffett's Advice and Be Greedy TheStreet.com
Jun-01-19 11:44AM  Here is the 7th Most Popular Stock Among Hedge Funds Insider Monkey
May-31-19 04:28PM  Dow Jones Today: A Miserable May Ends in Miserable Fashion InvestorPlace
02:53PM  7 Stocks to Sell in June InvestorPlace
01:54PM  Final trades: Johnson & Johnson, Charles Schwab, MacroGenics & more CNBC Videos
01:46PM  Johnson & Johnson Ordered to Pay $300 Million Punitive Award in Talc Case TheStreet.com
01:30PM  Johnson & Johnson To Pay $300M In Punitive Damages In Olson Talc Cancer Case Benzinga
01:04PM  Here is the Most Popular Stock Among Hedge Funds Insider Monkey
01:00PM  Johnson & Johnson falls on $300 million punitive award in NY talc trial CNBC Videos
12:53PM  J&J ordered to pay $300 million in punitive damages in talc baby powder case. Vows to appeal CNBC
08:24AM  FT Health: Time to reclassify tobacco? Financial Times
May-30-19 07:01PM  Jim Cramer: This Is Now an Emotional Market TheStreet.com
05:45PM  Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know Zacks
01:56PM  Johnson & Johnson Analyst: 3 Takeaways On Opioid Litigation Benzinga
10:52AM  Johnson & Johnsons Stock Slide From Opioid Trial Worries Is Overdone Barrons.com
10:06AM  Teva Stock Is Falling Because an Analyst Says the Company Needs Numerous Litigation Wins Barrons.com
09:42AM  Thursdays Vital Data: Johnson & Johnson, Baidu and Bank of America InvestorPlace
May-29-19 07:13PM  It's Getting Emotional: Cramer's 'Mad Money' Recap (Wednesday 5/29/19) TheStreet.com
07:12PM  Time to slowly start buying into market weakness: Cramer CNBC Videos
06:48PM  Jim Cramer: It's time to start buying amid market weakness, but take it slow CNBC Videos
06:32PM  Jim Cramer: It's time to start buying amid market weakness, but take it slow CNBC
05:56PM  Buffett's Berkshire Hathaway Closes Below $300,000 TheStreet.com
05:14PM  U.S. football player's overdose death spotlighted in J&J Oklahoma opioid trial Reuters
05:01PM  Dow Jones Today: Trade War, Specter of Recession Are Toxic for Stocks InvestorPlace
04:54PM  U.S. football player's overdose death spotlighted in J&J Oklahoma opioid trial Reuters
04:45PM  Capri, Abercrombie tumble; Marvell Technology rises Associated Press
04:15PM  Johnson & Johnson Stock Falls as Its Opioid Trial Gets Underway Barrons.com
04:14PM  After Another Stock Market Sell-Off, Here's The Biggest Question For Investors Investor's Business Daily
04:02PM  4 Top Stock Trades for Thursday: DKS, LULU, XOM, JNJ InvestorPlace
02:12PM  J&J Slide Deepens as Legal Woes Weigh on Shares Again Bloomberg
12:35PM  Band-Aids Cannot Help Johnson & Johnson in This Decline TheStreet.com
10:34AM  Allergan's (AGN) Vraylar Gets FDA Nod for Bipolar Depression Zacks
09:48AM  States must lead the way in fight against opioid epidemic, says former Maryland attorney general CNBC Videos
09:42AM  Teva Settles With Oklahoma, Shares Fall Following Downgrade Zacks
08:27AM  Should You Sell J&J Stock As Opioid Charges Heat Up? InvestorPlace
08:20AM  10 Best Stocks to Buy and Hold Forever InvestorPlace
07:28AM  Johnson & Johnson, Oklahoma come out swinging in first day of historic opioid trial CBS News Videos
01:26AM  PRESS DIGEST- New York Times business news - May 29 Reuters
May-28-19 10:41PM  Families impacted by the opioid crisis watching landmark trial CBS MoneyWatch
08:59PM  J&J's greed helped fuel U.S. opioid crisis, Oklahoma claims at trial Reuters
08:57PM  Johnson & Johnson's greed helped fuel U.S. opioid crisis, Oklahoma claims at trial Reuters
08:54PM  J&J's greed helped fuel U.S. opioid crisis, Oklahoma claims at trial Reuters
06:13PM  Oklahoma attorney blames corporate greed for opioid crisis Associated Press
05:15PM  Teva Plummets on Downgrade Following $85M Opioid Settlement TheStreet.com
04:54PM  J&J's greed helped fuel U.S. opioid crisis, Oklahoma claims at trial Reuters
04:28PM  J&J's greed helped fuel U.S. opioid crisis, Oklahoma claims at trial Reuters
03:39PM  The Latest: Drugmakers say products were heavily regulated Associated Press
03:36PM  This Just In: Goldman Sachs Picks 4 Big Pharma Stocks to Buy Motley Fool
02:39PM  4 Drug and Health Stocks Pushing Higher InvestorPlace
01:24PM  Oklahoma at trial says J&J's deceptive marketing fuelled U.S. opioid crisis Reuters
01:04PM  Factbox: Oklahoma becomes first U.S. state to take drugmaker to trial over opioids Reuters
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; sterilization and disinfection products to reduce surgical infection; diabetes care products; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. It has research and collaboration alliance with Morphic Therapeutic. The company was incorporated in 1887 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HEWSON MARILLYN ADirectorJun 11Buy139.683,000419,0403,000Jun 11 05:01 PM
Sneed Michael EEVP, Global Corp Aff & COOFeb 11Option Exercise0.007,275051,687Feb 12 09:14 PM
Mesquita Jorge S.Exec VP, WW Chair, ConsumerFeb 11Option Exercise0.0016,968036,138Feb 12 09:14 PM
McEvoy AshleyEVP, WW Chair, Medical DevicesFeb 11Option Exercise0.007,541021,809Feb 12 09:14 PM
Gorsky AlexChairman, CEOFeb 11Option Exercise0.0073,9470414,703Feb 12 09:14 PM
Duato JoaquinVice Chair, Exec CommitteeFeb 11Option Exercise0.0022,6240122,430Feb 12 09:14 PM
Kapusta Ronald AController, CAOFeb 11Option Exercise0.002,839018,231Feb 12 09:15 PM
Wolk Joseph JExec VP, CFOFeb 11Option Exercise0.002,903014,405Feb 12 09:15 PM
Fasolo PeterExec VP, Chief HR OfficerFeb 11Option Exercise0.0012,609093,947Feb 12 09:15 PM
Wengel Kathryn EEVP, Chief GSC OfficerFeb 11Option Exercise0.006,722044,546Feb 12 09:15 PM
Stoffels PaulusVice Chair, Exec CommitteeFeb 11Option Exercise0.0031,4280242,246Feb 12 09:15 PM
Ullmann Michael HExec VP, General CounselFeb 11Option Exercise0.0013,2730139,434Feb 12 09:15 PM
Taubert Jennifer LEVP, WW Chair, PharmaceuticalsFeb 11Option Exercise0.009,748078,388Feb 12 09:15 PM
Taubert Jennifer LEVP, WW Chair, PharmaceuticalsFeb 08Option Exercise0.008,529072,205Feb 12 09:15 PM
Ullmann Michael HExec VP, General CounselFeb 08Option Exercise0.005,3090128,294Feb 12 09:15 PM
Stoffels PaulusVice Chair, Exec CommitteeFeb 08Option Exercise0.0012,5710215,138Feb 12 09:15 PM
Wengel Kathryn EEVP, Chief GSC OfficerFeb 08Option Exercise0.005,882040,197Feb 12 09:15 PM
Fasolo PeterExec VP, Chief HR OfficerFeb 08Option Exercise0.005,044083,371Feb 12 09:15 PM
Wolk Joseph JExec VP, CFOFeb 08Option Exercise0.002,540012,239Feb 12 09:15 PM
Kapusta Ronald AController, CAOFeb 08Option Exercise0.002,484016,125Feb 12 09:15 PM
Duato JoaquinVice Chair, Exec CommitteeFeb 08Option Exercise0.009,0490102,604Feb 12 09:14 PM
Gorsky AlexChairman, CEOFeb 08Option Exercise0.0029,5790352,464Feb 12 09:14 PM
McEvoy AshleyEVP, WW Chair, Medical DevicesFeb 08Option Exercise0.006,599016,092Feb 12 09:14 PM
Mesquita Jorge S.Exec VP, WW Chair, ConsumerFeb 08Option Exercise0.006,787022,179Feb 12 09:14 PM
Sneed Michael EEVP, Global Corp Aff & COOFeb 08Option Exercise0.006,365046,239Feb 12 09:14 PM
PRINCE CHARLESDirectorDec 14Buy134.372,000268,73128,520Dec 17 08:37 AM
MULCAHY ANNE MDirectorDec 14Buy133.76748100,0506,537Dec 17 08:37 AM
PEREZ WILLIAM DDirectorDec 14Buy133.911,000133,9109,122Dec 17 08:37 AM
Kapusta Ronald AController, CAODec 13Sale147.313,643536,63813,641Dec 14 04:33 PM
Fasolo PeterExec VP, Chief HR OfficerDec 04Option Exercise96.7341,5634,020,237119,890Dec 06 05:27 PM
Fasolo PeterExec VP, Chief HR OfficerDec 04Sale146.6841,5636,096,55278,327Dec 06 05:27 PM
Fasolo PeterExec VP, Chief HR OfficerDec 03Option Exercise94.12125,13211,777,919203,459Dec 06 05:27 PM
Fasolo PeterExec VP, Chief HR OfficerDec 03Sale146.32125,13218,308,68978,327Dec 06 05:27 PM
Sneed Michael EEVP, Global Corp Aff & COONov 23Option Exercise58.3330,9431,804,90570,817Nov 27 06:56 PM
Sneed Michael EEVP, Global Corp Aff & COONov 23Sale142.4630,9434,407,98539,874Nov 27 06:56 PM
Gorsky AlexChairman, CEONov 16Option Exercise62.39264,46516,500,026601,024Nov 16 07:44 PM
Gorsky AlexChairman, CEONov 16Sale145.96264,46538,600,968336,559Nov 16 07:44 PM
Kapusta Ronald AController, CAONov 08Sale145.158,4411,225,20017,284Nov 09 05:22 PM
Duato JoaquinVice Chair, Exec CommitteeNov 07Option Exercise62.9440,0002,517,526133,555Nov 09 05:20 PM
Duato JoaquinVice Chair, Exec CommitteeNov 07Sale144.3640,0005,774,48093,555Nov 09 05:20 PM
Kapusta Ronald AController, CAOSep 07Sale137.187,8991,083,60725,725Sep 11 03:53 PM
Sneed Michael EEVP, Global Corp Aff & COOAug 27Option Exercise58.3329,0001,691,57059,124Aug 28 04:03 PM
Sneed Michael EEVP, Global Corp Aff & COOAug 27Sale134.8029,0003,909,08430,124Aug 28 04:03 PM